Irtemazole

This classification denotes a uricosuric agent with the molecular formula C18H16N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AAK27WY74I, chemically known as 1h-benzimidazole, 5-(1h-imidazol-1-ylphenylmethyl)-2-methyl-, (+-)- but generally known as irtemazole, which bears US NIH Compound Identifier 71330. European Medicines Agency schedules Irtemazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08300MIG. The term IRTEMAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). IRTEMAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule irtemazole under HS 29332990 and SITC 51573. As of Q4 2014, IRTEMAZOLE remains the US FDA Preferred Term for this commodity. Irtemazole bears US NLM identifiers UMLS ID C0063880 and NCI Concept Code C65965. SMILES: N1(C(C2CC3[NH]C(NC3CC2)C)C2CCCCC2)CCNC1.